Cutting Edge: Serum but Not Mucosal Antibody Responses Are Associated with Pre-Existing SARS-CoV-2 Spike Cross-Reactive CD4+ T Cells following BNT162b2 Vaccination in the Elderly.
J Immunol
; 208(5): 1001-1005, 2022 03 01.
Article
Dans Anglais
| MEDLINE | ID: covidwho-1674946
ABSTRACT
Advanced age is a main risk factor for severe COVID-19. However, low vaccination efficacy and accelerated waning immunity have been reported in this age group. To elucidate age-related differences in immunogenicity, we analyzed human cellular, serological, and salivary SARS-CoV-2 spike glycoprotein-specific immune responses to the BNT162b2 COVID-19 vaccine in old (69-92 y) and middle-aged (24-57 y) vaccinees compared with natural infection (COVID-19 convalescents, 21-55 y of age). Serological humoral responses to vaccination excee-ded those of convalescents, but salivary anti-spike subunit 1 (S1) IgA and neutralizing capacity were less durable in vaccinees. In old vaccinees, we observed that pre-existing spike-specific CD4+ T cells are associated with efficient induction of anti-S1 IgG and neutralizing capacity in serum but not saliva. Our results suggest pre-existing SARS-CoV-2 cross-reactive CD4+ T cells as a predictor of an efficient COVID-19 vaccine-induced humoral immune response in old individuals.
Texte intégral:
Disponible
Collection:
Bases de données internationales
Base de données:
MEDLINE
Sujet Principal:
Vieillissement
/
Lymphocytes T CD4/
/
Anticorps neutralisants
/
SARS-CoV-2
/
Vaccin BNT162
/
Anticorps antiviraux
Type d'étude:
Étude pronostique
/
Essai contrôlé randomisé
Les sujets:
Vaccins
Limites du sujet:
Adulte
/
Adulte très âgé
/
Femelle
/
Humains
/
Mâle
/
Adulte d'âge moyen
/
Jeune adulte
langue:
Anglais
Revue:
J Immunol
Année:
2022
Type de document:
Article
Pays d'affiliation:
Jimmunol.2100990
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS